Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

Inclusion Criteria:

• locally advanced pancreatic cancer
• performance status 0-2
• normal blood count and chemistry
• no previous chemotherapy or radiotherapy

Exclusion Criteria:

• serious concurrent systemic disease